Nektar Therapeutics (NKTR)

Every figure this model derived for NKTR, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 244,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 684,341,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 739,402,000 AssetsCurrent 2026-06-30
current liabilities 70,985,000 LiabilitiesCurrent 2026-06-30
equity 903,121,000 StockholdersEquity 2026-06-30
ocf -233,788,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 54,589,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 11,985,000 AllocatedShareBasedCompensationExpense 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up NKTR on one particular measure came for.

RatioValue
cash operating margin-234.58
current ratio10.42
current ratio reported10.42
deferred revenue growth-98.35
dilution pct23.07
fcf margin-428.72
operating margin-257.8
owner earnings margin-450.67
revenue growth-27.15
revenue growth per share-40.8
roic-50.82
rule of 40-284.95
sbc pct revenue21.95

What to be careful about

What this model itself distrusts about NKTR's figures. Written by the derivation as it ran, not added afterwards.